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Tomas Jerlström f, Annica Löfgren a, Oliver Patschan a,b, Anne Sörenby a,b, Mats Bläckberg c
a Institution of Translational Medicine, Lund University, Malmö, Sweden; bDepartment of Urology, Skåne University Hospital, Malmö, Sweden; cDepartment
of Urology, Helsingborg County Hospital, Helsingborg, Sweden; dDepartment of Urology, Landspitali University Hospital, Reykjavik, Iceland; eRegional
Cancer Centre South, Region Skåne, Lund, Sweden; fDepartment of Urology, School of Health and Medical Sciences, Örebro University, Örebro, Sweden
E U R O P E A N U R O L O G Y 7 8 ( 2 0 2 0 ) 7 5 7 – 7 6 3
ava i lable at www.sc iencedirect .com
journa l homepage: www.europea nurology.com
Article info
Article history:












Background: Parastomal hernia (PSH) after urinary diversion with ileal conduit is
frequently a clinical problem.
Objective: To investigate whether a prophylactic lightweight mesh in the sublay position
can reduce the cumulative incidence of PSH after open cystectomy with ileal conduit.
Design, setting, and participants: From 2012 to 2017, we randomised 242 patients 1:1 to
conventional stoma construction (n = 124) or prophylactic mesh (n = 118) at three
Swedish hospitals (ISRCTN 95093825).
Outcome measurements and statistical analysis: The primary endpoint was clinical PSH,
and secondary endpoints were radiological PSH assessed in prone position with the
stoma in the centre of a ring, parastomal bulging, and complications from the mesh.
Results and limitations: Within 24 mo, 20/89 (23%) patients in the control arm and 10/
92 (11%) in the intervention arm had developed a clinical PSH (p = 0.06) after a median
follow-up of 3 yr, corresponding to a hazard ratio of 0.45 (confidence interval 0.24–0.86,
p = 0.02) in the intervention arm. The proportions of radiological PSHs within 24 mo
were 22/89 (25%) and 17/92 (19%) in the two study arms. During follow-up, five patients
in the control arm and two in the intervention arm were operated for PSH. The median
operating time was 50 min longer in patients receiving a mesh. No differences were
noted in proportions of Clavien-Dindo complications at 90 d postoperatively or in
complications related to the mesh during follow-up.
Conclusions: Prophylactic implantation of a lightweight mesh in the sublay position
decreases the risk of PSH when constructing an ileal conduit without increasing the risk
of complications related to the mesh. The median surgical time is prolonged by mesh
implantation.
Patient summary: In this randomised report, we looked at the risk of parastomal hernia
after cystectomy and urinary diversion with ileal conduit with or without the use of a
prophylactic mesh. We conclude that such a prophylactic measure decreased the
occurrence of parastomal hernias, with only a slight increase in operating time and
no added risk of complications related to the mesh.
© 2020 The Authors. Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY license (http://creativecommons.
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The literature offers very little information on the occur-
rence of parastomal hernias (PSHs), and the proportion of
patients being subjected to surgical repair after radical
cystectomy and ileal conduit [1]. Studies in this context are
often hampered by simultaneous reporting of several types
of long-term complications after cystectomy, by the use of
single-centre design, and by not applying time-to-event
statistics [2,3]. Furthermore, these retrospective investiga-
tions include only limited numbers of patients. In the
largest available review [4], which considered a total of
3170 patients treated with radical cystectomy and ileal
conduit, the proportions reported to have a clinical PSH
diagnosis ranged from 4% to 28%, and even larger
proportions were noted for patients with a radiological
diagnosis of PSH.
In that review, surgical repair was offered to 8–75% of the
patients with PSHs, and recurrence following repair ranged
from 27% to 50% [4].
There are currently conflicting results from randomised
studies investigating the use of a prophylactic mesh on the
effect on PSH when creating a colostomy [5,6]. It seems that
the application of such a prophylactic lightweight mesh in
the sublay position when performing an ileal conduit after
radical cystectomy does not generate mesh-related com-
plications [7,8]. Considering that a PSH constitutes a
significant clinical problem for the individual patient, we
performed a prospective randomised multicentre study to
ascertain whether the use of a prophylactic mesh can decre
the risk of developing clinical PSH.
2. Patients and methods
2.1. Patients and recruitment
Out of 432 patients subjected to radical cystectomy and ileal conduit,
242 accepted study inclusion at two university hospitals (Skåne
University Hospital in Malmö [n = 97] and Örebro University Hospital
in Örebro [n = 69]) and one county hospital (Helsingborg County Hospital
in Helsingborg [n = 76]) in Sweden between August 2012 and May
2017. Randomisation was performed using closed envelopes without
blinding. Inclusion criteria were cystectomy and ileal conduit in a patient
>18 yr of age in combination with the absence of a previous stoma.
Exclusion criteria were previous stoma and a lack of informed consent.
2.2. Surgical details of mesh insertion
Preoperatively, the stoma location was marked on the skin by a stoma
nurse within the area of the right rectus abdominis muscle, except in
Örebro University Hospital where it was performed by the operating
urologist. A Vypro mesh (10 cm  10 cm; Ethicon) was used. Further
details are given in the Supplementary material (surgical methods).
2.3. Follow-up, surveillance, outcomes, and mode of
measurement
The primary endpoint clinical PSH and the secondary endpoints
radiological PSH, parastomal bulging, and complications from the mesh
were assessed at follow-up visits at 6, 12, and 24 mo postoperatively, aswell as at later visits scheduled at the discretion of the treating urologist.
The occurrence of a clinical PSH and bulging around the stoma were
registered without any a priori definitions applied for clinical PSH or
parastomal bulging, and both symptomatic and asymptomatic findings
were reported. At the same time intervals, patients underwent computed
tomography (CT) for oncological follow-up. This was done with the
patient in the prone position, with the stoma placed in the centre of an
inflatable plastic ring, which is reported to correlate with clinical PSH
(kappa value 0.80) [9]. The CT scan was performed during simultaneous
straining, adding assessment of radiological hernia to oncological
outcomes at the evaluation of the CT by the radiologist. At the end of
follow-up, all patients had at least one follow-up visit to assess clinical
PSH, but the exact number of clinical visits was not registered. The
physicians and radiologists assessing for PSH were not blinded to the
randomisation arm. During follow-up, some patients were referred to
additional CT examinations, and also after 24 mo additional CT
investigations were performed to rule out bladder cancer metastases
at the discretion of the treating urologist. The exact number of CT
investigations per patient was not registered as these not were
performed in prone position. However, the information was used if a
PSH was reported in any of these investigations, even if not performed in
prone position. Of all patients, 203 had undergone at least one CT scan in
prone position during follow-up as described above, equally distributed
between the control group and the intervention group (83% and 85%,
respectively). The CT scans showing a PSH were reviewed (F.L. and T.J.)
and classified according to the study of Moreno-Matias et al [10] as
follows: I = a hernia sac containing stoma loop; II = a hernia sac
containing the omentum; and III = a hernia sac containing an intestinal
loop other than the stoma loop. A retrospective review of patient charts
was conducted to obtain information on postoperative complications at
90 d after surgery and on long-term complications related to PSH and
mesh implantation.
The study was registered on a trial site (ISRCTN 95093825) and
approved by the Research Ethics Board of Lund University (2012/336).
2.4. Statistics
We anticipated 20% clinical PSHs in the control arm [4] and 5% in the
intervention arm at 2 yr, based on reported proportions of PSHs after
using prophylactic mesh in general surgery from two small randomised
trials [11,12]. Considering that approximately 50% of randomised bladder
cancer patients will succumb to the disease within 2 yr of surgery, we
doubled the required sample size and planned to enrol 240 patients in
the present study to achieve a power of 0.8 to detect a reduction in PSH
rate from 20% to 5% (a = 0.05) at 2-yr follow-up. In analysis of the data,
continuous variables were tabulated using median and interquartile
ranges (IQRs). When appropriate, statistical comparisons were per-
formed with a standard t test. Categorical variables were tabulated and,
when applicable, were compared using a chi-square test. This was done
except when small classes made it inappropriate, and in such cases,
Fisher's exact test was used and noted accordingly. The primary endpoint
PSH was assessed by survival analysis methods, with follow-up time
representing the time to PSH if observed, as were secondary endpoints
radiological PSH and parastomal bulging. In other circumstances,
patients were censored at the date of last clinical follow-up or the date
of death. At the end of follow-up, 157 patients were alive. The primary
analysis was a time-to-event analysis comparing the patients who were
and those who were not treated with a mesh instead of the binary
endpoint (PSH within 24 mo) used when performing the power
calculation described above. The reason for this was emerging
knowledge published after the start of the study, reporting occurrence
of PSH also after 2 yr and progression to more severe hernias in more
than one out of three patients during further follow-up [13]. The risks of
clinical and radiological PSH and parastomal bulging were analysed by
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following covariates: mesh or no mesh, operating hospital, body mass
index (BMI; per increased unit), and use of preoperative chemotherapy.
All analyses were performed using the R package, version 3.6.1 [14]. The
CONSORT checklist for reporting randomised trials are available in the
Supplementary material.
3. Results
A total of 242 patients scheduled to undergo open radical
cystectomy for bladder cancer and ileal conduit were
randomised 1:1 to prophylactic mesh implantation or
conventional stoma formation (Fig. 1). One patient ran-
domised to the control group had severe adhesions after
previous abdominal surgery, and it was not technically
feasible to construct an ileal conduit; this patient instead
received a ureteroureteric anastomosis and unilateral
nephrostomy. The patient and treatment characteristics
of the 241 evaluable individuals were well balanced
between the study groups (Table 1), and the median
follow-up time after cystectomy was 3 (IQR 2–4) yr in the
control group and 3 (IQR 2–5) yr in the mesh group, for
patients without PSH. Within 6, 12, and 24 mo, 5/117 (4%), 9/
103 (9%), and 20/89 (23%) patients in the control arm and 1/
111 (1%), 7/100 (7%), and 10/92 (11%) patients in the
intervention arm, respectively, had developed a clinical PSH
(Table 2). The corresponding proportions of radiological
PSHs within 24 mo were 22/89 (25%) and 17/92 (19%; not
significant), and the raw numbers at the end of follow-up
are reported in Table 3. Parastomal bulging with no hernia
was a clinical finding within 24 mo in 13/89 (15%) patients
without a prophylactic mesh and 22/92 (24%) with a mesh
(not significant). The cumulative incidence of clinical PSH in
the two treatment arms is illustrated in Fig. 2, correspond-Fig. 1 – A CONSORT-diagram descing to a hazard ratio (HR) of 0.45 (confidence interval [CI]
0.24–0.86, p = 0.02).
When investigating the risk of clinical PSH in a
multivariable Cox proportional hazard model adjusting
for mesh or no mesh according to randomisation, operating
hospital, BMI (per increased unit), and use of preoperative
chemotherapy, prophylactic mesh (HR 0.49 [CI 0.26–0.95,
p = 0.04]), BMI (HR 1.08 per unit [CI 1.01–1.16, p = 0.02]), and
surgery in one of the hospitals (HR 3.34 [CI 1.39–8.06, p =
0.007]) were associated with such a risk (Supplementary
Table 1). Corresponding associations with the secondary
endpoints radiological PSH and parastomal bulging are
given in Supplementary Tables 2 and 3, respectively. The
median operating time was 50 min longer for patients who
received a prophylactic mesh than for those who did not
(415 vs 365 min; p = 0.007). However, no increases in the
rates of postoperative Clavien-Dindo grade 1–2 and 3–5
complications at 90 d were observed in patients with a
mesh compared with those without (Table 1). One patient in
the intervention arm (ie, with a prophylactic mesh)
developed postoperative partial ischaemia in the ileal
conduit, and one patient in the control arm (ie, without a
mesh) developed complete ischaemia in the ileal conduit
and had to undergo a reoperation within 90 d of the primary
surgery. No other potential mesh-related complications
were observed within 90 d of surgery (Table 4). During
follow-up, five patients in the control arm and two in the
intervention arm were operated for PSH. Another patient in
the control arm had a reoperation for an elongated stoma,
and one additional patient in the intervention arm had a
reoperation on the ileal conduit for a flat stoma bud and this
was performed locally without the need for laparotomy.
One patient in the intervention arm had a minor stomal
prolapse at follow-up, which was treated conservatively.ribing the study population.






Age (yr), median (IQR) 71 (66–76) 71 (65–74)
Gender, n (%)
Male 97 (79) 91 (77)
Female 26 (21) 27 (23)
Operating hospital, n (%)
Skåne University Hospital 47 (38) 50 (42)
Helsingborg County Hospital 40 (33) 35 (30)
Örebro University Hospital 36 (29) 33 (28)
ASA score, n (%)
1 14 (12) 14 (12)
2 73 (61) 67 (57)
3–4 33 (28) 37 (31)
Missing 3 –
Smoking status, n (%)
Nonsmoker 34 (29) 39 (36)
Previous smoker 62 (53) 44 (40)
Current smoker 20 (17) 27 (25)
Missing 7 8
BMI, median (IQR) 26 (24–28) 26 (22–28)
Previous inguinal hernia repair, n (%)
No 109 (91) 107 (91)
Yes 11 (9) 11 (9)
Missing 3 –
Current inguinal hernia, n (%)
No 114 (95) 114 (97)
Yes 6 (5) 4 (3)
Missing 3 –
Previous midline laparotomy, n (%)
No 115 (97) 112 (98)
Yes 4 (3) 3 (3)
Missing
Neoadjuvant or induction chemotherapy, n (%)
No 78 (63) 66 (56)
Yes 45 (37) 52 (45)
Intra- and postoperative characteristics
Adjuvant chemotherapy, n (%)
No 116 (94) 110 (94)
Yes 7 (6) 7 (6)
Extent of lymphadenectomy, n (%)
Aortic bifurcation 27 (22) 33 (28)
Iliac bifurcation 86 (70) 74 (63)
Obturator fossa/none 10 (8) 11 (9)
Primary urethrectomy, n (%) 35 (28) 24 (21)
Perioperative bleeding (ml), median (IQR) ml 500 (325–800) 450 (300–700)
Suture to wound length ratio, median (IQR) 5 (4–6) 5 (4–6)
Operation time (min), median (IQR) 365 (305–450) 415 (340–480)
Highest Clavien-Dindo grade complication at 90 d, n (%)
1–2 19 (15) 21 (18)
3–5 30 (24) 32 (27)
ASA = American Society of Anesthesiologists; BMI = body mass index; IQR = interquartile range.
Table 2 – Number of patients with a clinical parastomal hernia out





Clinical parastomal hernia within 6 mo 5/117 1/111
Clinical parastomal hernia within 12 mo 9/103 7/100
Clinical parastomal hernia within 24 mo 20/89 10/92
The denominators in the table are all patients alive at the time points
reported.
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intervention arm developed a midline incisional hernia.
4. Discussion
The prophylactic use of a lightweight mesh in the sublay
position decreased the proportion of clinical PSHs within
24 mo from 23% to 11%, corresponding to a relative risk of
0.45 (CI 0.24–0.86) at 3-yr median follow-up. During follow-
up, surgery for PSH was performed in five patients in the
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PSH = parastomal hernia.
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proportion of Clavien-Dindo grade 3–5 complications
within 90 d after surgery was similar in the two study
arms, and no mesh-related complications were noticed at
long-term follow-up. In a multivariable Cox proportional
hazard analysis, use of a prophylactic mesh (HR 0.49 [CI
0.26–0.95]), BMI (HR 1.08 per unit [CI 1.01–1.16]), andFig. 2 – Cumulative incidence of clinical parastomal hernia (HR 0.45 [C
Table 4 – Distribution of Clavien grade 3–5 complications 90 d after su
Number of patients with Clavien-Dindo grade 3–5 complications at 90 d a
Wound dehiscence 
Stenosis or insufficiency in ureterointestinal anastomosis 
Insufficiency in the enteroenteroanastomosis 
Lymphocele treated with percutaneous drainage 
Postoperative bleeding with reoperation 
Postoperative infection (unspecified) 
Cardiovascular or thromboembolic events 
Other causes of Clavien-Dindo grade 3–5 complications surgery in one of the hospitals (HR 3.34 [CI 1.39–8.06]) were
associated with the risk of PSH.
We have performed the only randomised study thus far
to evaluate the use of a prophylactic mesh when construct-
ing an ileal conduit. One of the limitations of the
investigation is the lack of information on how the selection
of patients was performed, that is, data specifically showing
how many of the screened patients were considered
ineligible for the study or denied participation and the
characteristics of these patients compared with the
randomised cohort. Furthermore, our study was not
blinded, and the strategy of adding anterior fixation of
the conduit to the rectus sheath in both study arms could be
questioned when considering the hypothesis-generating
findings reported in a recently published retrospective
study [15]. Inasmuch as robotic-assisted laparoscopic
cystectomy was not included in the present study protocol,
the findings cannot be generalised to the robotic setting,
even if it is possible to place a sublay mesh in such patients
when performing minimally invasive radical cystectomy
and ileal conduit [16]. Another limitation of our investiga-I 0.24–0.86, p = 0.02]). CI = confidence interval; HR = hazard ratio.
rgery between the study arms (Fischer’s exact test).
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progression of hernia size occurs in one out of three
patients [13,17], and a longer follow-up might have added
further PSH events taking into account that PSHs have been
reported up to 27 yr after surgery [18]. In this context, the
diminishing number of patients at risk during follow-up is
another study limitation, as are the over-representation of
individuals with older age, lower BMI, and more severe
comorbidity among individuals without any information
about the primary outcome clinical PSH beyond 24 mo of
follow-up (Supplementary Table 4). This leads to an
underestimation of the risk of PSH in a healthier population
than in the present study, although not affecting the
primary outcome measure as the mortality is distributed
equally between the study arms.
The low rate of mesh-related complications observed in
the present study is similar to the findings reported by other
investigators [7,8]. However, one of the patients operated
for a PSH in the control arm received a sublay lightweight
mesh at surgical repair, and that patient suffered from
erosion of the mesh into the conduit, which required a
surgical revision. The rate of PSH of 23% within 24 mo in the
control arm of the present study resembles that reported in
the literature [4], although many published studies have not
considered time-to-event analyses. The lack of valid
assessment tools to investigate stoma and peristomal
complications [19] is also problematic when analysing
our results, together with a lack of several factors that might
affect the healing process postoperatively such as diabetes
mellitus and immunosuppression, both regarding the risk of
PSH and mesh-related complications.
The effect size of the intervention in our study was
smaller than that in a recent systematic review evaluating
the use of a prophylactic sublay mesh when constructing
stomas in general surgery [6], which demonstrated 37% PSH
in the control arm but only 16% PSH in the intervention arm
(odds ratio 0.24 [CI 0.12–0.50]). However, generalisation of
the outcome of the present study and recommendation of a
prophylactic mesh in all patients receiving an ileal conduit
must be balanced against the longer operating time.
However, it is also possible that a larger effect size with
more events can occur during longer follow-up and that
proper health-economic analyses can add information to
the decision regarding whether to use a prophylactic mesh
when constructing an ileal conduit. Some institutions have
already been using a prophylactic sublay mesh in obese and
female patients when performing ileal conduits [8], and this
seems relevant when considering the outcome of the
present study—an 8% increased risk of PSH per increased
BMI unit was noted in the present study. The knowledge
that ileal conduit formation in women with incontinence
might also be associated with an increased risk of PSH
further supports the use of a prophylactic mesh in these
patients [20]. On the contrary, the evolution of new less
extensive procedures to repair PSHs that obviate the need
for a laparotomy [21] must also be weighed into the decision
of whether a prophylactic mesh should or should not be
used.5. Conclusions
The use of a prophylactic lightweight mesh reduces the risk
of PSH after ileal conduit construction without causing any
mesh-related complications, although with a prolonged
operating time. Especially in obese patients who are at risk
for developing PSHs, such a prophylactic measure can be
recommended based on the present results; however, with
longer follow-up and health-economic analyses, the use of a
prophylactic mesh at surgery can be defined further.
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